Plain-English translation of NCT06066138 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach to giving , a medication that helps your immune system fight certain cancers. Instead of using the standard fixed dose for everyone, researchers want to see if they can personalize the dose based on blood tests that measure how much medication is in your body. The goal is to find the lowest effective dose while still keeping the medication working well.
Current dosing gives much higher amounts of this medication than may actually be needed, which can increase side effects and costs. This study wants to find out if monitoring blood levels and adjusting doses individually can maintain the treatment's effectiveness while reducing unnecessary exposure.
You likely qualify if…
You likely don't qualify if…
You would receive infusions on a schedule determined by your doctor, either alone or combined with other approved cancer drugs. Throughout a 16-week study period, you will have regular blood tests to measure how much medication is in your body, and your dose may be adjusted based on those results. Your doctor will monitor you closely for side effects and how well the treatment is working against your cancer.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States